California-based Ambys Medicines has launched with $140m in funding to develop treatments for serious liver diseases. The company is working on a drug that targets the enzyme responsible for producing acetyl CoA and other compounds which can damage liver, kidneys or blood vessels. ’s Takeda, while another $80m was secured through a further partnership agreement with Takeda. Redwood City, California-based Ambys Medicines announced its launch Wednesday, with a $60 million Series A funding round led by Boston-based Third Rock Ventures and Ambys will focus on the development of therapeutic modalities such as cell therapy, hepatocyte transplantation and gene therapy for the treatment of patients with chronic liver diseases.
California-based Ambys Medicines has launched with $140m in funding to develop treatments for serious liver diseases. The company is working on a drug that targets the enzyme responsible for producing acetyl CoA and other compounds which can damage liver, kidneys or blood vessels. ’s Takeda, while another $80m was secured through a further partnership agreement with Takeda. Ambys will focus on the development of therapeutic modalities such as cell therapy, hepatocyte transplantation and gene therapy for the treatment of patients with chronic liver diseases.